The anti-PD-L1 scFv produced from CF33-hNIS-antiPDL1-infected cancer cells has the potential to block PD-L1, preventing the PD-L1-PD1-mediated exhaustion of CD8+ T cells. This evidence concerns the gene CD8A and cancer.